NCT05448755Phase 2Completed

A Study of ELX-02 in Patients With Alport Syndrome

Study sponsor: Eloxx Pharmaceuticals, Inc. · ELOX

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-09-11Actual

Enrollment · participants3Actual

Source updated2026-02-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-02-24 · 6 fields changed

Primary outcomes · main study measures

Text edit · unverified significance

− Previous value

measure: The incidence and characteristics of adverse events

+ Updated value

measure: Number of Participants With Adverse Events Associated With Administration of 0.75 mg/kg of ELX-02 Once Daily

The saved outcome text may be shortened. Check the source for full wording.

Participant count type

Recorded edit

− Previous value

Estimated

+ Updated value

Actual

Enrollment · participant count

Recorded edit

− Previous value

count: 8; type: ESTIMATED

+ Updated value

count: 3; type: ACTUAL

Completion date type

Recorded edit

− Previous value

Estimated

+ Updated value

Actual

Primary completion date

Recorded edit

− Previous value

2023-05-30

+ Updated value

2023-09-11

Recruitment status

Recorded edit

− Previous value

Recruiting

+ Updated value

Completed

Check registry source

Study details

Conditions studied

Alport Syndrome

Treatments or interventions studied

ELX-02Drug

Primary outcomes · main study measures

Read the study measures

measure: Number of Participants With Adverse Events Associated With Administration of 0.75 mg/kg of ELX-02 Once Daily; description: Treatment Emerging Adverse Events were defined as any adverse events with onset after the first administration of study medication through the end of the study, or any event that was present at baseline but worsened in intensity or was subsequently considered drug-related by the Investigator through the end of the study. Severe Treatment Emerging Adverse Event is a Treatment Emerging Adverse Events with CTCAE Grade 3 or above. Related Treatment Emerging Adverse Events is defined as a Treatment Emerging Adverse Events with a certain, probable/likely, or possible relationship to the study drug. Serious Adverse Events were Adverse Events resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening.; timeFrame: From the time of first dosing through the end of the follow-up period, a total of 5 months

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history